Literature DB >> 27502933

Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement.

Dai Chihara1, Nathan H Fowler1, Yasuhiro Oki1, Michelle A Fanale1, Luis E Fayad1, Jason R Westin1, Fredrick B Hagemeister1.   

Abstract

Entities:  

Keywords:  zzm321990EPOCHzzm321990; CNS lymphoma; diffuse large B-cell lymphoma; high-dose methotrexate

Mesh：

Substances：

Year:  2016        PMID： 27502933      PMCID： PMC6063086          DOI： 10.1111/bjh.14267

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  8 in total

1.  Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.

Authors:  Lauren E Abrey; Tracy T Batchelor; Andrés J M Ferreri; Mary Gospodarowicz; Elisa J Pulczynski; Emanuele Zucca; Justine R Smith; Agnieszka Korfel; Carole Soussain; Lisa M DeAngelis; Edward A Neuwelt; Brian Patrick O'Neill; Eckhard Thiel; Tamara Shenkier; Fransesc Graus; Martin van den Bent; John F Seymour; Philip Poortmans; James O Armitage; Franco Cavalli
Journal:  J Clin Oncol       Date:  2005-06-13       Impact factor: 44.544

2.  Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.

Authors:  Lisa M DeAngelis; Wendy Seiferheld; S Clifford Schold; Barbara Fisher; Christopher J Schultz
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

3.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

4.  Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy.

Authors:  Felix Bokstein; Alexander Lossos; Izidore S Lossos; Tali Siegal
Journal:  Leuk Lymphoma       Date:  2002-03

5.  Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?

Authors:  Raja B Khan; Weiji Shi; Howard T Thaler; Lisa M DeAngelis; Lauren E Abrey
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

6.  High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial.

Authors:  Andrés J M Ferreri; Giovanni Donadoni; Maria Giuseppina Cabras; Caterina Patti; Michael Mian; Renato Zambello; Corrado Tarella; Massimo Di Nicola; Alfonso M D'Arco; Gianluca Doa; Marta Bruno-Ventre; Andrea Assanelli; Marco Foppoli; Giovanni Citterio; Alessandro Fanni; Antonino Mulè; Federico Caligaris-Cappio; Fabio Ciceri
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

7.  How I treat CNS lymphomas.

Authors:  James L Rubenstein; Neel K Gupta; Gabriel N Mannis; Amanda K Lamarre; Patrick Treseler
Journal:  Blood       Date:  2013-08-20       Impact factor: 22.113

8.  Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.

Authors:  Wyndham H Wilson; Kieron Dunleavy; Stefania Pittaluga; Upendra Hegde; Nicole Grant; Seth M Steinberg; Mark Raffeld; Martin Gutierrez; Bruce A Chabner; Louis Staudt; Elaine S Jaffe; John E Janik
Journal:  J Clin Oncol       Date:  2008-03-31       Impact factor: 44.544
  8 in total
  5 in total

Review 1.  SOHO State of the Art Updates and Next Questions: Prophylaxis and Management of Secondary CNS Lymphoma.

Authors:  Jillian Simard; Mark Roschewski
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2022-06-06

2.  HBV infection potentiates resistance to S-phase arrest-inducing chemotherapeutics by inhibiting CHK2 pathway in diffuse large B-cell lymphoma.

Authors:  Xinying Zhao; Xudong Guo; Libo Xing; Wenqin Yue; Haisen Yin; Miaoxia He; Jianmin Wang; Jianmin Yang; Jie Chen
Journal:  Cell Death Dis       Date:  2018-01-19       Impact factor: 8.469

3.  Treatment of adult Burkitt lymphoma with the CALGB 1002 protocol: a single center experience in Jordan.

Authors:  Mohammad Ma'koseh; Rula Amarin; Faris Tamimi; Baha' Sharaf; Alaa Abufara; Omar Shahin; Mohammed K M Manassra; Khalid Halahleh
Journal:  Blood Res       Date:  2021-12-31

4.  Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-center retrospective study.

Authors:  Megan Fleming; Ying Huang; Emily Dotson; David A Bond; John Reneau; Narendranath Epperla; Lapo Alinari; Jonathan Brammer; Beth Christian; Robert A Baiocchi; Kami Maddocks; Yazeed Sawalha
Journal:  Ther Adv Hematol       Date:  2022-07-23

5.  R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement.

Authors:  Maximilian J Steinhardt; Franziska C Krummenast; Andreas Rosenwald; Elena Gerhard-Hartmann; Anke Heidemeier; Hermann Einsele; Max S Topp; Johannes Duell
Journal:  J Cancer Res Clin Oncol       Date:  2021-06-03       Impact factor: 4.553
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.